StockData
Alpha Cognition Inc. logo

Alpha Cognition Inc. (ACOG) stock

ACOGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/3066% above fair value
$8.30−0.26 (-3.04%)

Close on Nov 13, 2026Market cap $180.76MP/E –Yield –

Alpha Cognition r&d expenses

Research and development expenses are spending on new products and technology.

Alpha Cognition's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.00M, up 111.7% year over year. For fiscal 2025 it was $1.87M, down 52.4% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.87M-52.4%
FY2024Dec 31, 2024$3.92M-19.7%
FY2023Dec 31, 2023$4.88M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.34M+161.8%
Q2 FY2026Jun 30, 2026$2.01M+394.6%
Q1 FY2026Mar 31, 2026$1.10M+173.8%
Q4 FY2025Dec 31, 2025$547.63K-47.4%
Q3 FY2025Sep 30, 2025$513.78K-48.4%
Q2 FY2025Jun 30, 2025$406.14K-58.0%
Q1 FY2025Mar 31, 2025$400.42K-56.3%
Q4 FY2024Dec 31, 2024$1.04M-6.3%
Q3 FY2024Sep 30, 2024$996.03K-30.3%
Q2 FY2024Jun 30, 2024$967.20K-22.4%
Q1 FY2024Mar 31, 2024$916.72K–
Q4 FY2023Dec 31, 2023$1.11M–
Q3 FY2023Sep 30, 2023$1.43M–
Q2 FY2023Jun 30, 2023$1.25M–

More Alpha Cognition figures

See a number that looks wrong?